 |
|
A Controlled Trial of Naltrexone Augmentation of Nicotine Replacement Therapy for Smoking Cessation
Stephanie S. O’Malley, PhD;
Judith L. Cooney, PhD;
Suchitra Krishnan-Sarin, PhD;
Joel A. Dubin, PhD;
Sherry A. McKee, PhD;
Ned L. Cooney, PhD;
Amy Blakeslee, BS;
Boris Meandzija, MD;
Denise Romano-Dahlgard, APRN;
Ran Wu, MS;
Robert Makuch, PhD;
Peter Jatlow, MD
Arch Intern Med. 2006;166:667-674.
Background Many smokers remain refractory to current therapies, which only partially address weight gain after smoking cessation. Thus, this study evaluated whether naltrexone hydrochloride augmentation of nicotine patch therapy improves smoking abstinence and reduces postcessation weight gain more than nicotine patch therapy alone and at what dose.
Methods Six-week double-blind placebo-controlled trial with follow-up in an outpatient research center. Four hundred individuals who smoked 20 or more cigarettes daily were randomly assigned to treatment for 6 weeks with a 21-mg nicotine patch and oral naltrexone hydrochloride (0, 25, 50, or 100 mg/d) after equal random treatment assignment and followed up for 1 year after randomization. The a priori specified primary end points were prolonged 4-week cigarette abstinence after a 2-week grace period in the intent-to-treat sample and weight gain in these abstainers.
Results We found no significant differences in prolonged 4-week abstinence (P = .49) or 6-week continuous abstinence after the quit date (P = .12) during treatment in the intent-to-treat analysis. Among 295 treatment completers, the 100-mg dose was associated with higher continuous abstinence rates (71.6%) compared with placebo (48%) (odds ratio, 2.73; 95% confidence interval, 1.39-5.39; P<.01). Among continuous abstainers, the 25-mg naltrexone hydrochloride group gained significantly less weight (mean ± SEM, 0.7 ± 0.31 kg) than the placebo group (mean ± SEM, 1.9 ± 0.33 kg; P<.01). Similar naltrexone dose effects on weight were found for those with prolonged abstinence and treatment completers, irrespective of abstinence.
Conclusions The 100-mg dose of naltrexone hydrochloride appears the most promising for augmenting the efficacy of the nicotine patch on smoking cessation outcomes but requires further study. The significant weight reduction with low-dose naltrexone therapy suggests that it may be useful as a second-line treatment for weight-concerned smokers.
Author Affiliations: Departments of Psychiatry (Drs O’Malley, Krishnan-Sarin, McKee, N. L. Cooney, and Meandzija and Mss Blakeslee, Romano-Dahlgard, and Wu), Epidemiology and Public Health (Drs Dubin and Makuch), and Laboratory Medicine (Dr Jatlow), Yale University School of Medicine, New Haven, Conn; Department of Psychiatry, University of Connecticut Health Center, Farmington (Dr J. L. Cooney); and Veterans Affairs Connecticut Healthcare System, Newington (Drs J. L. Cooney and N. L. Cooney). Dr Dubin is now with the Department of Statistics and Health Studies, University of Waterloo, Waterloo, Ontario.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Rationale for transdermal drug administration in Alzheimer disease
Oertel et al.
Neurology 2007;69:S4-S9.
ABSTRACT
| FULL TEXT
Smoking kills (alcoholics)! shouldn't we do something about it?
Littleton et al.
Alcohol Alcohol 2007;42:167-173.
ABSTRACT
| FULL TEXT
|
